|Bid||59.21 x 900|
|Ask||59.45 x 800|
|Day's range||58.83 - 60.88|
|52-week range||21.06 - 66.47|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||40.67|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
DUBLIN, November 21, 2022--Prothena announced that it has earned a $40 million milestone payment from Novo Nordisk.
DUBLIN, November 03, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third quarter and first nine months of 2022 and provided a business update.
DUBLIN, November 03, 2022--Prothena Corporation plc today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at ASH 2022.